NGL Fine Chem Ltd
Established in 1981, NGL Fine-Chem Limited manufactures human and veterinary bulk drugs, intermediates, and formulations. It primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters [1]
- Market Cap ₹ 1,107 Cr.
- Current Price ₹ 1,792
- High / Low ₹ 2,824 / 1,702
- Stock P/E 26.8
- Book Value ₹ 454
- Dividend Yield 0.10 %
- ROCE 20.4 %
- ROE 17.0 %
- Face Value ₹ 5.00
Pros
Cons
- Earnings include an other income of Rs.18.4 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Part of BSE Allcap BSE Healthcare BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
153 | 152 | 258 | 318 | 278 | 339 | 372 | |
121 | 130 | 178 | 249 | 243 | 285 | 321 | |
Operating Profit | 32 | 22 | 80 | 68 | 35 | 54 | 51 |
OPM % | 21% | 14% | 31% | 21% | 13% | 16% | 14% |
4 | 1 | 8 | 11 | 6 | 14 | 18 | |
Interest | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
Depreciation | 6 | 8 | 8 | 10 | 11 | 12 | 12 |
Profit before tax | 28 | 12 | 78 | 67 | 27 | 54 | 56 |
Tax % | 27% | 31% | 27% | 25% | 25% | 24% | |
20 | 8 | 57 | 50 | 20 | 41 | 41 | |
EPS in Rs | 32.58 | 13.50 | 91.81 | 80.77 | 33.18 | 66.88 | 66.98 |
Dividend Payout % | 5% | 13% | 2% | 2% | 5% | 3% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 10% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | -10% |
TTM: | 19% |
Stock Price CAGR | |
---|---|
10 Years: | 35% |
5 Years: | 33% |
3 Years: | -13% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 18% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 89 | 96 | 151 | 200 | 219 | 260 | 277 |
27 | 28 | 16 | 30 | 32 | 34 | 49 | |
23 | 26 | 36 | 44 | 32 | 59 | 66 | |
Total Liabilities | 142 | 154 | 207 | 277 | 287 | 356 | 396 |
61 | 68 | 64 | 89 | 88 | 86 | 89 | |
CWIP | 0 | 0 | 12 | 6 | 26 | 46 | 61 |
Investments | 9 | 11 | 29 | 29 | 39 | 54 | 79 |
73 | 75 | 102 | 153 | 133 | 171 | 167 | |
Total Assets | 142 | 154 | 207 | 277 | 287 | 356 | 396 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
9 | 20 | 27 | 14 | 35 | 20 | |
-10 | -20 | -25 | -14 | -27 | -27 | |
0 | -1 | -1 | -1 | -1 | -1 | |
Net Cash Flow | -1 | -0 | 2 | -1 | 7 | -7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 79 | 63 | 53 | 74 | 86 | 97 |
Inventory Days | 106 | 155 | 132 | 137 | 69 | 98 |
Days Payable | 92 | 116 | 103 | 91 | 63 | 112 |
Cash Conversion Cycle | 93 | 102 | 82 | 120 | 93 | 83 |
Working Capital Days | 107 | 93 | 76 | 117 | 105 | 110 |
ROCE % | 14% | 54% | 34% | 12% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
16 Nov - Transcript of Q2 FY25 earnings conference call.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Nov - Company participated in investors conference call on Q2 results.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Investor presentation for Q2 & H1 FY25 results.
-
Disclosure under Regulation 30A of LODR
11 Nov - Submission of newspaper publication of financial results.
-
Financial Results
8 Nov - Approved unaudited financial results for Q2 FY2024-25.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT REC
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
Dec 2019TranscriptPPT
Product Portfolio FY24
Presently, Veterinary APIs are the main product of the company which account for 89% of its revenues, followed by Veterinary Formulations (5%), Human APIs (3%), and Intermediates (3%).[1] The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms.[2]